Genetic Engineering & Biotechnology News

06/23/2026

AbbVie to Acquire Apogee Therapeutics for $10.9B

AbbVie has agreed to acquire Apogee Therapeutics for $10.9 billion, in a deal designed to bolster the buyer’s pipeline with an atopic dermatitis (AD) candidate set to advance to Phase III trials during the second half of this year, and being positioned as a potential challenger to a top-selling drug. Don't miss Alex Philippidis' reporting from BIO.

I am Biotech

AbbVie has agreed to acquire Apogee Therapeutics for $10.9 billion, in a deal designed to bolster the buyer’s pipeline with an atopic dermatitis (AD) candidate set to advance to Phase III trials during the second half of this year, and being positioned as a potential challenger to a top-selling dr...

06/22/2026

Impact of Early Life Adversity on Epigenome at Molecular Level Mapped in Macaques

The Arizona State University and Vanderbilt University team created highly precise tissue-specific clocks, capable of predicting age within about one year of an individual’s chronological age.

The team created highly precise tissue-specific clocks, capable of predicting age within about one year of an individual’s chronological age.

06/22/2026

StockWatch: Positive Phase III Data Sells Investors on Intellia Therapeutics

CEO John Leonard, MD, speaks with GEN's Alex Philippidis after lonvo-z meets secondary endpoints in Phase III HAELO trial; Shares surge 29% over four days as analysts conclude the in vivo CRISPR gene editing candidate merits U.S. Food and Drug Administration. Plus other leaders and laggards: Elicio Therapeutics, Neumora Therapeutics, and uniQure.

A second positive Phase III data readout in two months is a major reason why Intellia Therapeutics shares have soared more than 76% over the past six months—including a 29% surge this past week that followed the CRISPR gene editing therapy developer’s lead pipeline candidate lonvoguran ziclumera...

06/21/2026

Bacterial Expression Tech Prompts NorthX and enGenes Collaboration

Interest in E.coli-based expression systems is growing as biopharma firms look for faster and cheaper ways of making proteins at commercial scale, prompting the new partnership between NorthX Biologics and Biotech.

bioprocessing

NorthX Biologics and enGenes Biotech team to develop an integrated, bacterial-based protein production platform.

06/21/2026

Solvent Recovery Gains Ground in Bioprocessing

As bioprocessors face rising solvent costs, supply-chain disruptions, and mounting sustainability demands, solvent-recovery systems are emerging as strategic investments that reduce operating expenses, strengthen production resilience, and help companies meet increasingly ambitious environmental goals.

Koch Modular Process Systems, LLC

Solvent recovery helps bioprocessors cut costs, improve resilience, and efficiently advance sustainability goals.

06/20/2026

Analytics Map Purification Optimization Tradeoffs

Chromatography optimization should be considered not only in terms of quality, but also in terms of how each change affects processing time, congestion, and feasibility regarding stability-based time windows.

Bilkent University

New framework helps biomanufacturers’ interventions, eyeing quality, cost, and stability for two-step chromatography decisions.

06/20/2026

Don't Miss Out: Immune Cell Phenotyping: Cell Surface Architecture Informs Disease Biology

Broadcast Date: Tuesday, June 23, 2026
Time: 07:00 PDT, 10:00 EDT, 16:00 CET

In this GEN webinar, Erdinc Sezgin, PhD, Karolinska Institutet, will present how his lab profiled plasma membrane order across 12 immune cell subtypes simultaneously in healthy donors and patients with long COVID and chronic lymphocytic leukemia.

Register for this free webinar sponsored by Pixelgen: https://hubs.li/Q04kD7j_0

06/19/2026

Continuous Production Platform Offers New Gene Therapy Options

An independent U.K. innovation center, the and Gene Therapy (CGT) Catapult, has developed a continuous bioprocess to improve productivity and reduce costs of advanced therapies. The new platform performs as well, or better, than batch methods.

Cell and Gene Therapy Catapult has developed a continuous bioprocessing platform for gene therapies.

06/18/2026

Perseverance, Persistence Key to CAR T Success, Say Ross Prize Winners Carl June and Michel Sadelain

The Feinstein Institutes Ross Prize recognizes biomedical scientists whose discoveries have transformed how medicine is practiced. This year's recipients are well known in immunotherapy circles for their efforts to develop CAR T cells now used in cancer therapeutics.

Northwell Health, Perelman School of Medicine at the University of Pennsylvania, Parker Institute for Cancer Immunotherapy, Columbia University Vagelos College of Physicians and Surgeons

In separate lectures presented during the award ceremony, both scientists spoke on the many benefits of and future directions for CAR T cells.

06/18/2026

Top 10 US Biopharma Clusters 2026

GEN's Alex Philippidis presents his latest edition of its nationally and regionally-cited annual A-List of its top 10 US biopharma cluster rankings, designed to show which regions are most competitive in attracting life sciences leaders, companies, and institutions. Over more than a decade, GEN has based its rankings on five criteria: patents, National Institutes of Health (NIH) funding, venture capital funding, laboratory space, and number of jobs:

Mid-cap buyers, improved capital raising climate, and reshoring of manufacturing are shaping how much and where biopharmas choose to grow.